Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment

Summary

In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded DC vaccine and conventional third-line therapy to patients with colorectal cancer (CRC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.

Timeline

Start

2024-09-01

Primary completion

2026-08-31

Completion

2027-02-28

Drugs

Indications